Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
5.15
-0.22 (-4.10%)
Dec 30, 2025, 11:31 AM EST - Market open
Radiopharm Theranostics Revenue
In the fiscal year ending June 30, 2025, Radiopharm Theranostics had annual revenue of 12.51M AUD with 538.86% growth. Radiopharm Theranostics had revenue of 10.07M in the half year ending June 30, 2025, with 417.19% growth.
Revenue (ttm)
12.51M AUD
Revenue Growth
+538.86%
P/S Ratio
7.52
Revenue / Employee
893,727 AUD
Employees
14
Market Cap
61.67M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 12.51M | 10.55M | 538.86% |
| Jun 30, 2024 | 1.96M | -4.25M | -68.46% |
| Jun 30, 2023 | 6.21M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
RADX News
- 14 days ago - Why Is Radiopharm Theranostics Stock Rallying Over 140%? - Benzinga
- 15 days ago - Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases - GlobeNewsWire
- 2 months ago - Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan - GlobeNewsWire
- 4 months ago - Radiopharm Theranostics Limited - Special Call - Seeking Alpha
- 5 months ago - Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update - GlobeNewsWire
- 5 months ago - Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board - GlobeNewsWire
- 7 months ago - Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake - GlobeNewsWire
- 8 months ago - ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177 - GlobeNewsWire